Uveitis, Posterior Clinical Trial
— OMOfficial title:
Ozurdex as Monotherapy for Treatment of Non-infectious Intermediate, Posterior, or Panuveitis
This study will investigate the efficacy and safety of OZURDEX® (dexamethasone intravitreal implants; DEX, Allergan, Inc. Irvine, CA) as monotherapy for the treatment of non-infectious intermediate-, posterior- or panuveitis. This is a prospective randomized controlled clinical trial taking place at the University of Ottawa Eye Institute, Ottawa, Ontario, Canada, and other possible centers in Canada. Consecutive consenting subjects who meet inclusion/exclusion criteria will be selected to participate in this study. The subjects must have either non-infectious intermediate, posterior, or panuveitis. The subjects will be randomly chosen to be part of one of two groups; one group will receive DEX as monotherapy and the other group will receive oral prednisone. Approximately 84 eyes (42 per arm) will take part in study. The primary outcome will measure the proportion of eyes with a vitreous haze score of 0 six months post initial treatment. Secondary measures will include best corrected visual acuity (BCVA), central retinal thickness (CRT) measured by spectral-domain optical coherence tomography (SD-OCT), time to vitreous haze resolution and time to failure defined at number of months with DEX implant until an adjunct therapy is indicated. Baseline measurements will be recorded within 1 month prior to treatment in both groups, with follow up measurements collected at 0, 1, 2, 4, 6 and 12 months post-operatively.
Status | Recruiting |
Enrollment | 84 |
Est. completion date | September 30, 2027 |
Est. primary completion date | September 30, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age =18 years - Diagnosis of non-infectious intermediate, posterior, or panuveitis in at least one eye - Active uveitic disease at Screening/Baseline defined by the presence of at least 1 of the following parameters: 1) Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion 2) = 1+ vitreous haze (NEI/SUN criteria) Exclusion Criteria: - Presence of isolated anterior uveitis - Evidence of macular edema due to diabetes, retinal vein occlusion or any other ocular conditions - Confirmed or suspected active ocular disease or infections - Intraocular surgery in the past 6 months - History of glaucoma - Intraocular pressure (IOP) of >21 mmHg at Screening/Baseline or confirmed normal-tension glaucoma - Intravitreal or periocular injection within 6 months prior to screening. - Unable to tolerate systemic corticosteroids - Prior topical corticosteroid within 1 month of screening - Prior non-steroidal anti-inflammatory, systemic steroids, or immunomodulatory therapy (e.g. methotrexate) within 1 month of screening - For women: pregnant or breast feeding, or planning to become pregnant while enrolled in the study |
Country | Name | City | State |
---|---|---|---|
Canada | Ottawa Hospital Research Institute - Vision Research Centre | Ottawa | Ontario |
Lead Sponsor | Collaborator |
---|---|
Ottawa Hospital Research Institute |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients with Vitreous Haze score of 0 at 6 months | This score (using NEI/SUN criteria) is used to grade intraocular inflammation based on vitreous cells and protein exudation. A lower score is indicative of less inflammation which is the goal when using either Ozurdex implant or a oral prednisone. | Measurements obtained at 6 months | |
Secondary | Best Corrected Visual Acuity at various time points | This score will be used to determine the functional outcome (visual acuity) with the treatments. | Measurements obtained at: 1 month, 2 months, 4 months, 6 months, 12 months | |
Secondary | Proportion of patients with vitreous haze improvement by 1, and 2 units from baseline to various time points | This score will be used to look at the degree of changes in the inflammation. | Measurements obtained at: 1 month, 2 months, 4 months, 6 months, 12 months | |
Secondary | Time to vitreous haze score of 0 from baseline to various time points | This will be used to assess if there are differences in time to achieving lowest possible inflammation amongst groups. | Measurements obtained at: 1 month, 2 months, 4 months, 6 months, 12 months | |
Secondary | Anterior chamber cells/flare from baseline to various time points | Using SUN grading criteria, the proportion of patients with cells grade 0, 0.5+, 1+, 2+, 3+, 4+ and flare grade of 0, 1+, 2+, 3+, 4+ will be determined at Month 6. | Measurements obtained at: 1 month, 2 months, 4 months, 6 months, 12 months | |
Secondary | Change in central average thickness (µm) from baseline to various time points | This score will be used to assess anatomical changes (e.g. cystoid macular edema) with treatment | Measurements obtained at: 1 month, 2 months, 4 months, 6 months, 12 months | |
Secondary | Change in central average volume (in mm3) from baseline to various time points | This score will be used to assess anatomical changes (e.g. cystoid macular edema) with treatment | Measurements obtained at: 1 month, 2 months, 4 months, 6 months, 12 months | |
Secondary | Change in National Eye Institute Visual Function Questionnaire 25 Score | This will be used to determine impact of disease on the subject's quality of life. The worst possible score is 0 while best is 100. The higher the score, the higher the subjective visual function. | Baseline and 12mo | |
Secondary | Incidence of complications | Measure complication of treatment including but not limited to cataracts formation, ocular hypertension, vitreous hemorrhage, and endophthalmitis. | Anywhere between baseline to 12 months | |
Secondary | Percentage of patients with Vitreous Haze score of 0 at various time points | This score (using NEI/SUN criteria) is used to grade intraocular inflammation based on vitreous cells and protein exudation. A lower score is indicative of less inflammation which is the goal when using either Ozurdex implant or a oral prednisone. | Measurements obtained at: 1 month, 2 months, 4 months, 6 months (primary outcome), 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00570479 -
Prophylactic Anecortave Acetate in Patients With a Retisert Implant
|
Phase 1 | |
Recruiting |
NCT05486468 -
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
|
Phase 3 | |
Terminated |
NCT03656692 -
Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
|
Phase 4 | |
Completed |
NCT02255032 -
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
|
Phase 2 | |
Completed |
NCT00035906 -
Research Study in Patients With Persistent Macular Edema
|
Phase 2 | |
Terminated |
NCT05070728 -
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI)
|
Phase 3 | |
Completed |
NCT02595398 -
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
|
Phase 3 | |
Recruiting |
NCT03066869 -
Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis
|
Phase 4 | |
Completed |
NCT01539577 -
A Long-Term Safety Study of OZURDEX® in Clinical Practice
|
N/A | |
Recruiting |
NCT05322070 -
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
|
Phase 4 | |
Recruiting |
NCT06085079 -
Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
|
Phase 4 | |
Completed |
NCT03145025 -
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
|
||
Withdrawn |
NCT01905124 -
Safety &Efficacy of CF101 to Subjects With Uveitis
|
Phase 2 | |
Completed |
NCT03598452 -
High-dose Intravitreal Injection of Ganciclovir for the Treatment of CMVR in HIV-negative Patients
|
N/A | |
Completed |
NCT02049476 -
Study of the Effectiveness of Ozurdex for the Control of Uveitis
|
Phase 4 | |
Completed |
NCT00404612 -
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
|
Phase 3 | |
Completed |
NCT00404742 -
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
|
Phase 3 | |
Completed |
NCT02952001 -
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
|
||
Not yet recruiting |
NCT06431373 -
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
|
Phase 3 | |
Completed |
NCT03097315 -
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
|
Phase 3 |